ABSTRACT
Consequently, MSF put pressure on the five major pharmaceutical companies involved in the UNAIDS Accelerating Access Initiative to match Cipla’s benchmark.
Merck’s response was to cut the price of its HIV/AIDS treatments for developing countries, including offering Crixivan at $600 and Stocrin at $500.
